AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Brief description of study
The purpose of the study is to evaluate how stopping tyrosine kinase inhibitors (TKI) will affect treatment-free remission in patients with chronic myeloid leukemia (CML) in chronic phase (CP). When the level of disease is very low, it's called molecular remission. TKIs are a type of medication that help keep this level low. However, after being in molecular remission for a specific amount of time, it may not be necessary to take tyrosine kinase inhibitors. It is not yet known whether stopping tyrosine kinase inhibitors will help patients with chronic myeloid leukemia in chronic phase continue or re-achieve molecular remission.
Clinical Study Identifier: s20-01374
ClinicalTrials.gov Identifier: NCT03817398
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
